Literature DB >> 17132503

Defect in glycosylation that causes muscular dystrophy.

Tamao Endo1, Hiroshi Manya.   

Abstract

Muscular dystrophies are a diverse group of inherited disorders characterized by progressive muscle weakness and wasting. The dystrophin-glycoprotein complex is composed of alpha-, beta-dystroglycan (DG), dystrophin and some other molecules. alpha- and beta-DG stabilize the sarcolemma by acting as an axis through which the extracellular matrix is tightly linked to the cytoskeleton. The relative molecular weights of alpha-DG differ in different tissues as a result of differential glycosylation. New findings indicate that disrupted glycosylation of alpha-DG results in a loss of ligand binding, giving rise to both progressive muscle degeneration and abnormal neuronal migration in the brain. This article discusses methods, including purification of alpha-DG and glycosyltransferase assays involved in alpha-DG glycosylation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17132503     DOI: 10.1016/S0076-6879(06)17011-1

Source DB:  PubMed          Journal:  Methods Enzymol        ISSN: 0076-6879            Impact factor:   1.600


  3 in total

1.  A novel fluorescent assay for T-synthase activity.

Authors:  Tongzhong Ju; Baoyun Xia; Rajindra P Aryal; Wenyi Wang; Yingchun Wang; Xiaokun Ding; Rongjuan Mi; Miao He; Richard D Cummings
Journal:  Glycobiology       Date:  2010-10-19       Impact factor: 4.313

2.  An N-glycosylation site on the beta-propeller domain of the integrin alpha5 subunit plays key roles in both its function and site-specific modification by beta1,4-N-acetylglucosaminyltransferase III.

Authors:  Yuya Sato; Tomoya Isaji; Michiko Tajiri; Shumi Yoshida-Yamamoto; Tsuyoshi Yoshinaka; Toshiaki Somehara; Tomohiko Fukuda; Yoshinao Wada; Jianguo Gu
Journal:  J Biol Chem       Date:  2009-03-09       Impact factor: 5.157

Review 3.  O-Mannosylation and human disease.

Authors:  Christina M Dobson; Samuel J Hempel; Stephanie H Stalnaker; Ryan Stuart; Lance Wells
Journal:  Cell Mol Life Sci       Date:  2012-11-01       Impact factor: 9.261

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.